EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies

117 views
July 9, 2024

Chapters

Evaluating Venetoclax & Obinutuzumab for CLL

00:00

Weighing Time-Limited Therapy Against Continuous Therapy

02:40

Comments 0
Login to view comments. Click here to Login